PT  - JOURNAL ARTICLE
AU  - Bassetti, Matteo
AU  - Magnè, Federica
AU  - Giacobbe, Daniele Roberto
AU  - Bini, Lorenzo
AU  - Vena, Antonio
TI  - New antibiotics for Gram-negative pneumonia
AID  - 10.1183/16000617.0119-2022
DP  - 2022 Dec 31
TA  - European Respiratory Review
PG  - 220119
VI  - 31
IP  - 166
4099  - https://publications.ersnet.org//content/31/166/220119.short
4100  - https://publications.ersnet.org//content/31/166/220119.full
SO  - EUROPEAN RESPIRATORY REVIEW2022 Dec 31; 31
AB  - Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by in vitro susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially Klebsiella pneumoniae carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline.Thanks to new antibiotics, there is hope in the future regarding treatment of pneumonia caused by Gram-negative bacilli. https://bit.ly/3sl2sVw